Stock Financial Ratios, Dividends, Split History

JLL / Jones Lang LaSalle Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)7,930.24
Enterprise Value ($M)7,700.34
Book Value ($M)3,434.80
Book Value / Share75.50
Price / Book2.45
NCAV ($M)-1,339.00
NCAV / Share-29.43
Price / NCAV-5.74
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 44,684,482
Weighted Average Number Of Diluted Shares Outstanding 45,260,563
Common Stock Shares Outstanding 44,828,779
Common Shares Outstanding 44,834,250
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.15
Return on Assets (ROA)0.08
Return on Equity (ROE)0.18
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.14
Income Statement (mra) ($M)
Revenue Before Reimbursements0.00
Real Estate Revenue Net5,429,603,000.00
Operating Income465.66
Net Income388.02
Earnings Per Share Basic8.63
Earnings Per Share Diluted8.52
Cash Flow Statement (mra) ($M)
Cash From Operations498.86
Cash from Investing-187.94
Cash from Financing-187.94
Identifiers and Descriptors
Central Index Key (CIK)1037976
Related CUSIPS
48020Q907 48020Q957 048020Q10

Split History

Stock splits are used by Jones Lang LaSalle Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

The ParkOne's Shibuya Honmachi: modern mansion living in downtown Tokyo

2018-06-19 scmp
Mitsubishi's The ParkOne brand is satisfying the high demand for luxury residential property in Tokyo's trendiest areas. (1-0)

CBRE Shells Out $290M to Buy FacilitySource from Warburg

2018-06-13 zacks
CBRE Group Inc. (CBRE - Free Report) has announced the acquisition of the procurement and facilities management solutions provider — FacilitySource, LLC — from Warburg Pincus. The company has shelled out approximately $290 million in cash for this acquisition, which is expected to considerably boost the delivery of integrated solutions to occupier clients. Founded in 2005, FacilitySource has carved a niche for itself over the years with its proprietary SaaS technology platform. (22-0)

UPDATE 1-Go Daddy founder Parsons buys revamped Arizona center for $133 mln

2018-06-12 reuters
NEW YORK (Reuters) - A real estate concern of Bob Parsons, founder of web hosting company Go Daddy, said on Tuesday it agreed to pay $133 million for a revamped retail center in a Phoenix suburb that was a major foreclosure in 2011 following the Great Recession. (1-0)

Jones Lang LaSalle (JLL) Down 5.5% Since Earnings Report: Can It Rebound?

2018-06-07 zacks
A month has gone by since the last earnings report for Jones Lang LaSalle Incorporated (JLL - Free Report) . Shares have lost about 5.5% in that time frame. (25-0)

Jones Lang LaSalle Incorporated (JLL) Sees Hammer Chart Pattern: Time to Buy?

2018-06-07 zacks
Jones Lang LaSalle Incorporated (JLL - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because JLL recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. (22-0)

CUSIP: 48020Q107